FSD PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.64 CAD | 0.00% |
|
-7.25% | -46.67% |
| Apr. 08 | FSD Pharma Receives Nasdaq Non-Compliance Notice | MT |
| Mar. 29 | FSD Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 35.64M 26.09M |
|---|---|---|---|---|---|
| Net income 2022 | -23M -16.83M | Net income 2023 | -17M -12.44M | EV / Sales 2022 | - |
| Net cash position 2022 | 16.46M 12.05M | Net cash position 2023 | 3.17M 2.32M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-1.26
x | P/E ratio 2023 |
-2
x | Employees | 17 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 82.63% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 week | -7.25% | ||
| Current month | -33.33% | ||
| 1 month | -28.09% | ||
| 3 months | -43.36% | ||
| 6 months | -56.16% | ||
| Current year | -46.67% |
1 week
0.58
0.69
1 month
0.580.98
Current year
0.581.48
1 year
0.582.23
3 years
0.582.83
5 years
0.5856.28
10 years
0.58188.94
| Managers | Title | Age | Since |
|---|---|---|---|
Zeeshan Saeed
CEO | Chief Executive Officer | 54 | 94-10-19 |
Anthony Durkacz
FOU | Founder | 47 | 94-10-19 |
Nathan Coyle
DFI | Director of Finance/CFO | 43 | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anthony Durkacz
FOU | Founder | 47 | 94-10-19 |
Donal Carroll
COO | Chief Operating Officer | 48 | 18-06-30 |
Lakshmi Kotra
BRD | Director/Board Member | 53 | 22-11-24 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 0.64 | +1.59% | 45,171 |
| 24-04-19 | 0.63 | -1.56% | 46,898 |
| 24-04-18 | 0.64 | 0.00% | 14,687 |
| 24-04-17 | 0.64 | -7.25% | 92,157 |
| 24-04-16 | 0.69 | -1.43% | 71,127 |
Delayed Quote Canadian Securities Exchange, April 23, 2024 at 03:59 pm EDT
More quotes
FSD Pharma Inc. is a Canada-based biotechnology company. The Company operates through two segments: Biotechnology and Strategic Investments. Its Biotechnology segment is focused on furthering the research and development of the Companyâs two primary drug candidates consisting of Lucid-MS and Lucid-PSYCH, as well as the development of UNBUZZD. The Companyâs Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial real estate property. Lucid-PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. UNBUZZD is a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle.
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -46.67% | 18.7M | |
| -0.49% | 103B | |
| +3.31% | 96.73B | |
| +1.66% | 21.31B | |
| -16.16% | 21.21B | |
| -6.82% | 18.79B | |
| -41.41% | 16.37B | |
| -22.87% | 13.68B | |
| +6.32% | 13.44B | |
| +21.46% | 10.98B |
- Stock Market
- Equities
- HUGE Stock
